argenx (ARGX) Stock Price, News & Analysis

+6.33 (+1.72%)
(As of 04/23/2024 ET)
Today's Range
50-Day Range
52-Week Range
340,242 shs
Average Volume
320,163 shs
Market Capitalization
$22.29 billion
P/E Ratio
Dividend Yield
Price Target

argenx MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.71 Rating Score
40.8% Upside
$528.16 Price Target
Short Interest
2.02% of Shares Sold Short
Dividend Strength
News Sentiment
0.78mentions of argenx in the last 14 days
Based on 17 Articles This Week
Insider Trading
Proj. Earnings Growth
From ($2.10) to $3.21 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.81 out of 5 stars

Medical Sector

214th out of 910 stocks

Biological Products, Except Diagnostic Industry

28th out of 153 stocks

ARGX stock logo

About argenx Stock (NASDAQ:ARGX)

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

ARGX Stock Price History

ARGX Stock News Headlines

argenx (NASDAQ:ARGX) Stock Rating Reaffirmed by HC Wainwright
This Apple-like Innovator is Revolutionizing Healthcare
AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.
argenx (NASDAQ:ARGX) Rating Reiterated by Wedbush
The Analyst Verdict: argenx In The Eyes Of 12 Experts
Here’s how to start a “Weekend Side Hustle” from your sofa
Here’s how you can start your very own “Weekend Side Hustle” right from the comfort of your sofa! It doesn't matter if you have a multi-million dollar retirement account… Or if you’re just starting out with a few thousand.
argenx SE (NASDAQ:ARGX) Short Interest Down 10.4% in March
Guru Fundamental Report for ARGX
Here’s Why argenx SE (ARGX) Pulled Back 23% in Q4
Key Takeaways From argenx Analyst Ratings
Reasons to Invest in argenx (ARGX)
See More Headlines
Receive ARGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for argenx and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
21 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$1.27 billion
Book Value
$69.22 per share


Free Float
Market Cap
$22.29 billion
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Mr. Timothy Van Hauwermeiren EMBA (Age 52)
    M.B.A., M.Sc., CEO & Executive Director
    Comp: $1.29M
  • Mr. Karl Gubitz (Age 54)
    Chief Financial Officer
    Comp: $843.26k
  • Ms. Karen Massey (Age 45)
    Chief Operating Officer
    Comp: $1.42M
  • Mr. Filip Borgions
    VP & Global Head of Technical Operations
  • Mr. Peter Ulrichts (Age 44)
    Chief Scientific Officer
  • Ms. Beth DelGiacco
    VP and Global Head of Corporate Communications & Investor Relations
  • Ms. Malini Moorthy (Age 54)
    General Counsel
  • Mr. Arjen Lemmen M.Sc. (Age 39)
    Vice President of Corporate Development & Strategy
  • Mr. Marc Schorpion (Age 65)
    Global Head of Human Resources
  • Ms. Andria Wilk (Age 50)
    Global Head of Quality

Should I Buy argenx Stock? ARGX Pros and Cons Explained


Here are some ways that investors could benefit from investing in argenx SE:

  • Positive clinical trial results for Vyvgart Hytrulo showing a 61% decline in the risk of relapse, indicating strong potential for revenue growth.
  • Market capitalization of $29.30 billion despite not posting a profit, showcasing investor confidence in the company's drug pipeline.
  • Potential acquisition target by larger pharmaceutical firms due to its robust drug pipeline focusing on severe autoimmune diseases.
  • Vyvgart Hytrulo's revenue generation potential and regulatory approval for treating various conditions could lead to significant cash flow gains.
  • High valuations in the biotechnology sector due to innovative treatments, making argenx SE an attractive investment option.


Investors should be bearish about investing in argenx SE for these reasons:

  • Company has never posted a profit, indicating potential financial risks for investors.
  • Reliance on a single revenue-generating product, Vyvgart Hytrulo, may pose concentration risk if the product faces challenges.
  • Uncertainty in the biotech industry regarding regulatory approvals and market acceptance of new treatments, leading to investment volatility.
  • Potential competition from other biopharmaceutical companies developing similar therapies, impacting market share and revenue growth.
  • Investors need to carefully assess the risks associated with investing in a company with a focus on autoimmune diseases and unproven profitability.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, April 10, 2024. Please send any questions or comments about these argenx pros and cons to

ARGX Stock Analysis - Frequently Asked Questions

Should I buy or sell argenx stock right now?

21 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for argenx in the last twelve months. There are currently 1 sell rating, 5 hold ratings, 14 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ARGX shares.
View ARGX analyst ratings
or view top-rated stocks.

What is argenx's stock price target for 2024?

21 brokers have issued twelve-month price targets for argenx's shares. Their ARGX share price targets range from $408.00 to $641.00. On average, they anticipate the company's share price to reach $528.16 in the next year. This suggests a possible upside of 40.8% from the stock's current price.
View analysts price targets for ARGX
or view top-rated stocks among Wall Street analysts.

How have ARGX shares performed in 2024?

argenx's stock was trading at $380.43 at the beginning of 2024. Since then, ARGX stock has decreased by 1.4% and is now trading at $375.08.
View the best growth stocks for 2024 here

Are investors shorting argenx?

argenx saw a drop in short interest in March. As of March 31st, there was short interest totaling 1,200,000 shares, a drop of 10.4% from the March 15th total of 1,340,000 shares. Based on an average trading volume of 332,500 shares, the days-to-cover ratio is presently 3.6 days.
View argenx's Short Interest

When is argenx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our ARGX earnings forecast

How were argenx's earnings last quarter?

argenx SE (NASDAQ:ARGX) issued its quarterly earnings results on Thursday, February, 29th. The company reported ($1.68) earnings per share for the quarter, missing the consensus estimate of ($1.23) by $0.45. The firm had revenue of $417.84 million for the quarter, compared to analyst estimates of $378.60 million. argenx had a negative net margin of 23.26% and a negative trailing twelve-month return on equity of 16.97%. During the same period in the prior year, the business earned ($0.70) EPS.

What other stocks do shareholders of argenx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other argenx investors own include Galapagos (GLPG), Kohl's (KSS), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Neurocrine Biosciences (NBIX), Pfizer (PFE), CRISPR Therapeutics (CRSP), Fate Therapeutics (FATE), NVIDIA (NVDA) and Sarepta Therapeutics (SRPT).

When did argenx IPO?

argenx (ARGX) raised $65 million in an initial public offering (IPO) on Thursday, May 18th 2017. The company issued 3,600,000 shares at $18.18 per share. Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Who are argenx's major shareholders?

argenx's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Allspring Global Investments Holdings LLC (0.09%), Raymond James & Associates (0.08%), Raymond James Financial Services Advisors Inc. (0.02%), Norden Group LLC (0.01%), Maryland State Retirement & Pension System (0.01%) and First Trust Direct Indexing L.P. (0.00%).

How do I buy shares of argenx?

Shares of ARGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ARGX) was last updated on 4/23/2024 by Staff

From Our Partners